An Illustration of Challenges in Respiratory Drug Development

Publish Date:
July 25, 2016
Philip Lake, PhD, Executive Director of Scientific Affairs, Respiratory, Chiltern and Jan De Backer, PhD, CEO, Fluidda

This webinar will examine past design issues, current techniques to raise standards and new technology which will aid future understanding.

Key Discussion Points:

  • Look at the importance of understanding clinical study design and the impact it has on specific patient populations.
  • Show examples of how study design has generated unexpected outcomes in relation to treatment response for FEV1 and exacerbations.
  • Discuss how critical Spirometry endpoints are important to many existing respiratory studies.
  • Review the limitations around existing lung function endpoints of FEV1 and FVC .
  • Highlight some of the factors which can be improved by active management to increase the power of studies and to improve the understanding of which patients are responsive to therapy.